Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Sarcoidosis Indication Strategy Report 2026: TNF, Trials and Deals
21 July 2026
Sarcoidosis indication strategy report covering epidemiology, TNF biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Latest Hotspot
8 min read
IgG4-related disease Indication Strategy Report 2026: CD19, Trials and Deals
21 July 2026
IgG4-related disease indication strategy report covering epidemiology, CD19 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Latest Hotspot
8 min read
Takayasu arteritis Indication Strategy Report 2026: IL-6R, Trials and Deals
21 July 2026
Takayasu arteritis indication strategy report covering epidemiology, IL-6R biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Latest Hotspot
8 min read
Antiphospholipid syndrome Indication Strategy Report 2026: C5, Trials and Deals
21 July 2026
Antiphospholipid syndrome indication strategy report covering epidemiology, C5 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Latest Hotspot
8 min read
Relapsing polychondritis Indication Strategy Report 2026: IL-6R, Trials and Whitespace
21 July 2026
Relapsing polychondritis indication strategy report covering epidemiology, IL-6R biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Latest Hotspot
8 min read
Behcet disease Indication Strategy Report 2026: TNF, Trials and Deals
21 July 2026
Behcet disease indication strategy report covering epidemiology, TNF biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Latest Hotspot
8 min read
VEXAS syndrome Indication Strategy Report 2026: UBA1, Trials and Deals
21 July 2026
VEXAS syndrome indication strategy report covering epidemiology, UBA1 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Latest Hotspot
8 min read
Cryopyrin-associated periodic syndromes Indication Strategy Report 2026: NLRP3, Trials and Deals
21 July 2026
Cryopyrin-associated periodic syndromes indication strategy report covering epidemiology, NLRP3 biology, active trials, competition and deal signals using...
Read →
Latest Hotspot
8 min read
Familial Mediterranean fever Indication Strategy Report 2026: MEFV, Trials and Deals
21 July 2026
Familial Mediterranean fever indication strategy report covering epidemiology, MEFV biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Latest Hotspot
8 min read
Adult-onset Still disease Indication Strategy Report 2026: IL-1β, Trials and Deals
21 July 2026
Adult-onset Still disease indication strategy report covering epidemiology, IL-1β biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Latest Hotspot
8 min read
Juvenile idiopathic arthritis Indication Strategy Report 2026: IL-6R, Trials and Deals
21 July 2026
Juvenile idiopathic arthritis indication strategy report covering epidemiology, IL-6R biology, active trials, competition and deal signals using PatSnap MCP...
Read →
Latest Hotspot
8 min read
Peripheral T-cell lymphoma Indication Strategy Report 2026: CD30, Trials and Deals
21 July 2026
Peripheral T-cell lymphoma indication strategy report covering epidemiology, CD30 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
<
1
<<
1376
1377
1378
1379
1380
>>
2135
>